Professor Richard Price
Contact information
Podcast interview
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Research groups
Ethiopian Clinic
Vietnam Hospital
Richard Price
Professor of Tropical Medicine
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria
- define the morbidity and mortality of vivax malaria
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials and implementation studies of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Individual patient data metanalyses of antimalarial efficacy studies
Timika, Papua, Indonesia
RSMM Hospital
Sumatra Site for IMPROV Study
Ex vivo Lab
Recent publications
-
Severe haemolysis during primaquine radical cure ofPlasmodium vivaxmalaria: two systematic reviews and individual patient data descriptive analyses
Yilma D. et al, (2023)
-
Adapting international clinical trials during COVID-19 and beyond
Thriemer K. et al, (2023), Clinical Trials, 174077452311542 - 174077452311542
-
Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
Abdel Hamid MM. et al, (2023), Wellcome Open Research, 8, 22 - 22
-
Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples.
MalariaGEN None. et al, (2023), Wellcome open research, 8
-
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function
Douglas NM. et al, (2022), The American Journal of Tropical Medicine and Hygiene
-
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
Watson JA. et al, (2022), eLife, 11